Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
bioAffinity Technologies Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BIAF
Nasdaq
2835
https://bioaffinitytech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for bioAffinity Technologies Inc
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
- Apr 9th, 2024 12:00 pm
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Apr 1st, 2024 1:49 pm
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
- Mar 8th, 2024 6:15 pm
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
- Mar 8th, 2024 5:45 pm
WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
- Mar 6th, 2024 3:45 pm
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
- Mar 6th, 2024 2:46 pm
bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung
- Mar 5th, 2024 1:00 pm
Here's Why We're A Bit Worried About bioAffinity Technologies' (NASDAQ:BIAF) Cash Burn Situation
- Mar 1st, 2024 11:21 am
bioAffinity Technologies News Update
- Feb 21st, 2024 1:00 pm
Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice
- Feb 6th, 2024 1:00 pm
bioAffinity Technologies In The News
- Jan 30th, 2024 1:00 pm
bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer
- Jan 23rd, 2024 1:00 pm
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
- Jan 5th, 2024 2:00 pm
bioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of Directors
- Dec 5th, 2023 1:00 pm
CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
- Nov 30th, 2023 1:00 pm
bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
- Nov 28th, 2023 1:00 pm
bioAffinity Technologies Teams with American Cancer Society to Raise Funds for Lung Cancer Screening
- Nov 15th, 2023 1:00 pm
bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 14th, 2023 9:01 pm
bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
- Nov 6th, 2023 1:00 pm
bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
- Oct 10th, 2023 12:00 pm
Scroll